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wholesale acquisition cost with consideration of contractual dis-
counts and patient co-payment. The primary economic endpoint
was cost per relapse avoided over a 4-year period of treatment.
RESULTS: The ARR varied across the ﬁve DMDs with inter-
feron beta-1a SC injection (Rebif®) showing the highest results
(0.72) and interferon beta-1a IM injection (Avonex®) the lowest
(0.26). Economic results showed signiﬁcant difference in the
cost-effectiveness ratio (CER) among the DMDs, with interferon
beta-1a SC injection (Rebif®) having the most favorable CER
(US$47958/relapse avoided) and interferon beta-1a IM injection
(Avonex®) having the least favorable (US$121,147/relapse
avoided). Interferon beta-1b SC injection (Betaseron®), 
glatiramer acetate SC injection (Copaxone®), and natalizumab
IV injection (Tysabri®) offer intermediate CER results of
US$48,345, US$68,440, and US$93,903 per relapse avoided,
respectively. CONCLUSION: Modeling absolute reduction 
in clinical endpoints provides a methodology for comparing 
clinical trials and demonstrates that the difference in cost-
effectiveness results among the DMDs is signiﬁcant.
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OBJECTIVE: To examine the cost-effectiveness of ropinirole for
the treatment of primary restless legs syndrome (RLS) versus the
alternative off-label therapies of pramipexole and pergolide.
METHODS: A cost-effectiveness analysis was conducted from
the societal perspective using a cohort of 10,000 United States
adults 45 years old and older with moderate-to-severe primary
RLS. A decision tree was used to model cost-effectiveness for a
two-year period following commencement of dopamine agonist
therapy. Outcome probabilities were obtained from a systematic
review of randomized controlled trials and observational studies.
Costs were derived from standard 2005 health care cost refer-
ences. Cost-effectiveness decision models were created for base-
case analyses. One-way and probabilistic sensitivity analyses
were conducted to test the robustness of the ﬁndings. RESULTS:
In terms of changes in the International Restless Legs Syndrome
Study Group Rating Scale (IRLS) score for RLS severity, per-
golide dominates ropinirole given the base-case. Pergolide is 
cost-saving when compared to both ropinirole and pramipexole,
resulting in a saving of $1687 and $556 per one-point improve-
ment in IRLS score. One-way sensitivity analyses indicated that
the IRLS scores for augmentation strongly inﬂuenced the calcu-
lated incremental cost effectiveness ratios (ICERs). Probabilistic
sensitivity analyses revealed variation in the results indicating a
lack of clear dominance. CONCLUSIONS: None of the thera-
pies is clearly dominant in terms of cost per IRLS score change.
Although ropinirole is currently the only U.S. Food and Drug
Administration (FDA) approved medication for the treatment of
RLS, it is not more cost-effective than alternate off-label
dopamine agonists prescribed for RLS.
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OBJECTIVE: To determine the effect of neutralizing antibodies
(NAbs) on the cost-effectiveness of disease-modifying agents
(DMAs) used to treat multiple sclerosis (MS). METHODS: A
cost-effectiveness model was developed using relapse rate and
disability progression endpoints from pivotal phase III trials of
currently approved DMAs for MS (interferon beta [IFNB]-1a IM
[Avonex], IFNB-1a SC [Rebif], IFNB-1b [Betaseron], and glati-
ramer acetate [GA; Copaxone]). The model was created from a
managed care perspective with time horizons of 24 and 48
months. Cost-effectiveness is expressed as a ratio of total uti-
lization costs per percent relative risk reduction for relapses and
disability progression; daily cost-effectiveness is shown as per
percentage point reduction. The incidence of NAbs and their
effect on efﬁcacy was obtained from prescribing information,
open-label extension studies of IFNB products, and a large pop-
ulation study. The model includes the following assumptions:
comparison of similar endpoints across different clinical trials;
constant adverse event rates among products; constant burden
of relapse over time; constant persistence/compliance rates
among products; similar laboratory testing/frequency among
IFNB products. A one-way sensitivity analysis was conducted to
test the robustness of the model to changes in NAb incidence.
RESULTS: At 24 months, the cost-effectiveness for disability
progression was $824 ($1.13/day) for IFNB-1a IM, $1222
($1.67/day) for IFNB-1a SC, $1150 ($1.57/day) for IFNB-1b,
and $2558 ($3.50/day) for GA. After the development of NAbs,
at 48 months cost-effectiveness was $1659 ($1.14/day) for
IFNB-1a IM, $2536 ($1.74/day) for IFNB-1a SC, $2433
($1.67/day) for IFNB-1b, and $5117 ($3.50/day) for GA. Results
were similar for relapse rate. Results of sensitivity analyses 
conﬁrmed the robustness of the model. CONCLUSIONS: NAbs
reduce the cost-effectiveness of IFNB products. IFNB-1a IM
(Avonex) was the most cost-efﬁcacious DMA before (24 months)
and after (48 months) the development of NAbs.
PNL8
ASSESSING THE COST-EFFECTIVENESS OF
IMMUNOMODULATORY THERAPIES FOR RELAPSING-
REMITTING MULTIPLE SCLEROSIS BASED ON LONG-TERM
DATA
Bell CF1, Graham JB1, Earnshaw SR1, Oleen-Burkey M2,
Castelli-Haley J2, Johnson KP3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2Teva
Neuroscience, Inc, Kansas City, MO, USA, 3University of Maryland,
Baltimore, MD, USA
OBJECTIVES: Using long-term follow-up data from clinical
trials, this analysis assesses the cost-effectiveness of ﬁve treat-
ment strategies in patients diagnosed with relapsing-remitting
multiple sclerosis (RRMS): symptom management alone (SMA)
and symptom management combined with subcutaneous glati-
ramer acetate (SCGA), intramuscular interferon beta-1-a (IM-
IFNb1-a), subcutaneous interferon beta-1-a (SC-IFNb1-a), or
subcutaneous interferon beta-1-b (SC-IFNb1-b). METHODS: A
literature-based Markov model was developed to assess the cost-
effectiveness of ﬁve treatment strategies for managing a hypo-
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thetical cohort of patients diagnosed with RRMS in the United
States (US). Health states were based on the Kurtzke expanded
disability status scale (EDSS) (higher EDSS scores = increased
disease severity). Relapse and disease progression transition
probabilities for SMA were obtained from natural history
studies. Treatment effects of the immunomodulatory therapies
were estimated by applying a percent reduction to the SMA 
transition probabilities and adjusting for neutralizing antibodies
(NAbs) and treatment discontinuation. Therapy-speciﬁc data
was obtained from clinical trials and long-term follow-up
studies. Transitions among health states occurred in 1-month
cycles for the lifetime of a patient. Costs (2005US$) and out-
comes were discounted at 3% annually. RESULTS: The incre-
mental cost per quality-adjusted life-year (QALY) is $258,465,
$303,008, $395,686, and $310,691 for SCGA, IM-IFNb1-a, 
SC-IFNb1-a and SC-IFNb1-b compared to SMA respectively.
Sensitivity analyses showed results were sensitive to changes in
utilities, disease progression rates, time horizon and
immunomodulatory therapy cost. CONCLUSIONS: Model
results indicated that the immunomodulatory therapies are both
more effective and more costly than SMA in treating RRMS.
Although the reported incremental cost-effectiveness ratios
(ICERs) are well above $50,000/QALY, not all economic evalu-
ations are bounded by this threshold and numerous interventions
with ICERs above this threshold have been deemed valuable by
patients, health care decision-makers and society. This model
suggests that of the immunomodulatory therapies for MS SCGA
is the most cost-effective.
PNL9
COST-EFFECTIVENESS OF TOPIRAMATE FOR MIGRAINE
PREVENTION: A MANAGED CARE PERSPECTIVE
Brown J1, Rupnow M2, Neumann PJ3, Friedman M1, Menzin J1
1Boston Health Economics, Inc, Waltham, MA, USA, 2Ortho-McNeil
Janssen Scientiﬁc Affairs, LLC,Titusville, NJ, USA, 3Tufts University
School of Medicine, Boston, MA, USA
OBJECTIVES: To estimate the cost-effectiveness of topiramate
(TPM) treatment for migraine prevention versus no preventive
treatment using newly available efﬁcacy and cost data.
METHODS: Model inputs included baseline migraine days per
month (base-case: 7), treatment discontinuation, treatment
response, cost of preventive therapy, cost of acute treatment per
attack (medical and pharmacy services), hours of work lost per
attack, and hourly wage. Model outcomes were expressed
monthly and included the number of migraine days averted, dis-
ability hours, total cost of preventive and acute treatment, and
lost wages. Model inputs were gathered from published litera-
ture, clinical studies of TPM in migraine prevention (double-
blind and open-label extensions), and census data. Unit costs for
resource use were obtained by analyzing actual payments of year
2004 medical claims from a large managed care database.
RESULTS: TPM treatment was associated with a mean reduc-
tion in migraine days of 2.4/month, and 6.5 fewer disability
hours. Acute treatment costs per patient per month (including
pharmacy and medical) were $39 lower ($100 versus $139) and
work loss was $65 lower ($125 versus $190) for TPM preven-
tive arm. The incremental monthly cost per patient of TPM pre-
ventive therapy was $109. Consequently, the total cost in TPM
arm was $5 higher than in no-preventive arm ($109-$39-$65);
incremental total cost per migraine day averted was $2 for TPM
versus no preventive therapy. Results are sensitive to the 
baseline migraine rate: as the rate increases, total cost of 
care decreases, with break-even at 7.4 migraine days/month.
CONCLUSIONS: Economic savings (direct and indirect costs)
associated with lower migraine frequency offset approximately
93% of the cost of preventive therapy, suggesting that TPM is a
cost-effective treatment for migraine prevention.
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OBJECTIVES: A new disease modifying agent for the treatment
of MS, natalizumab (Tysabri), was introduced to the market at
the end of 2004 and withdrawn in early 2005 because of two
cases (one fatal) of progressive multifocal leukoencephalopathy
(PML). In the event that natalizumab is reintroduced to the
market, the present study was conducted to assess the cost-
effectiveness of natalizumab compared to interferon beta-1a
(Avonex) and no treatment. Expected value of perfect informa-
tion (EVPI) and partial EVPI (PEVPI) analyses were conducted
to characterize the existing uncertainty in the model parameters.
METHODS: The main analytical technique used in this study
was incremental cost-effectiveness analysis using a Markov
model. Two-level Monte Carlo simulations were performed to
obtain the EVPI and PEVPI estimates. Health care costs were
derived from the literature. The Disability Status Scale (DSS) was
used as the measure of disability; utility values were assigned to
the 10 DSS disability states based on data from the literature.
Cost valuations were based on the direct health-care costs asso-
ciated with disease relapse and medical care in each disability
state expressed in 2005 US dollars. RESULTS: The Markov
cohort analysis returned the following costs and QALYs: No
Treatment—$175,790 and 30.971 QALYs; interferon beta-1a—
$830,861 and 34.391 QALYs; natalizumab—$1,076,327 and
34.497 QALYs. The incremental cost-effectiveness ratios for
interferon beta-1a and natalizumab compared to no treatment
were: interferon beta-1a—$191,541 per QALY gained; natal-
izumab—$255,399 per QALY gained. CONCLUSIONS: Model
inputs were based on a limited number of available studies and
the results should be interpreted with caution. Nevertheless, the
results of this preliminary analysis suggest that treatment with
interferon beta-1a is somewhat more cost-effective than natal-
izumab. The value of information results indicate that more
information about the transition probabilities and QALY para-
meters are necessary to reduce the uncertainty in the model.
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OBJECTIVES: Payers in Europe and North America have dif-
ferent policies on coverage of multiple sclerosis (MS) disease-
modifying agents (DMAs). With the introduction of Medicare
Part D and in the presence of substantial variation in analytical
methods used to examine cost-effectiveness (CE) of MS DMAs,
an assessment of the models’ features and parameters is neces-
sary to understand and interpret the CE results for clinical prac-
tice and health policy. This study compares the results of CE
models evaluating DMAs (interferon beta-1a, interferon beta-1b,
